Evidence map›Paper›PMID 31393655›Full record

ArticleRespirology (Carlton, Vic.)2019

Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis.

Yuben P Moodley, Tamera J Corte, Brian G Oliver, Ian N Glaspole, Andreja Livk, Jason Ito, Kirsten Peters, Richard Lipscombe, Tammy Casey, Dino B A Tan

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Respirology (Carlton, Vic.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yuben P MoodleySchool of Biomedical Sciences, University of Western Australia, Perth, WA, Australia.ORCID 0000-0002-0777-1196
Tamera J CorteNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-7096-9365
Brian G OliverWoolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
Ian N GlaspoleNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-5118-2890
Andreja LivkProteomics International, Perth, WA, Australia.
Jason ItoProteomics International, Perth, WA, Australia.
Kirsten PetersProteomics International, Perth, WA, Australia.
Richard LipscombeProteomics International, Perth, WA, Australia.
Tammy CaseyProteomics International, Perth, WA, Australia.
Dino B A TanSchool of Biomedical Sciences, University of Western Australia, Perth, WA, Australia.ORCID 0000-0001-9108-2360
Abterra Biosciences (United States) · USThe University of Sydney · AUThe University of Western Australia · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveIdiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease that has a poor 3-year median survival rate with unclear pathophysiology. Radiological features include bibasal, subpleural fibrosis and honeycombing while its pathology is characterized by fibroblastic foci and honeycombing. Proteomic analysis of circulating molecules in plasma may identify factors that characterize IPF and may assist in the diagnosis, prognostication and determination of pathogenic pathways in this condition.

methodsTwo independent quantitative proteomic techniques were used, isobaric tags for relative and absolute quantitation (iTRAQ) and multiple reaction monitoring (MRM), to identify differentially expressed plasma proteins in a group of IPF patients in comparison to healthy controls with normal lung function matched for age and gender.

resultsFive proteins were identified to be differentially expressed in IPF compared to healthy controls (upregulation of platelet basic protein and downregulation of actin, cytoplasmic 2, antithrombin-III, extracellular matrix protein-1 and fibronectin).

conclusionThis study further validates the combinational use of non-targeted discovery proteomics (iTRAQ) with targeted quantitation by mass spectrometry (MRM) of soluble biomarkers to identify potentially important molecules and pathways for pulmonary diseases such as IPF.

Indexed as

Idiopathic Pulmonary FibrosisActinsAntithrombin IIIbeta-ThromboglobulinBiomarkersExtracellular Matrix ProteinsFemaleFibronectinsGene Expression RegulationHumansMaleMass SpectrometryMiddle AgedProteomicsActinsAntithrombin IIIbeta-ThromboglobulinBiomarkersECM1 protein, humanExtracellular Matrix ProteinsFibronectinsPPBP protein, humanidiopathic pulmonary fibrosisisobaric tags for relative and absolute quantitationmultiple reaction monitoringproteomics

Identifiers

PMID31393655
OpenAlexW2967257527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.